REGENXBIO Inc. (RGNX) News

REGENXBIO Inc. (RGNX): $24.91

-0.50 (-1.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGNX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 459

in industry

Filter RGNX News Items

RGNX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RGNX News Highlights

  • RGNX's 30 day story count now stands at 5.
  • Over the past 5 days, the trend for RGNX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about RGNX are GENE, AMD and DRUG.

Latest RGNX News From Around the Web

Below are the latest news stories about REGENXBIO Inc that investors may wish to consider to help them evaluate RGNX as an investment opportunity.

Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress

Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.

Yahoo | January 11, 2022

RegenxBio kicks off late-stage clinical trial with AbbVie for eye disease treatment

Successful results from this trial would help pave the way for the company to seek Food and Drug Administration approval.

Yahoo | January 10, 2022

REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

Yahoo | January 10, 2022

Wedbush Reaffirms Their Hold Rating on RegenXBio (RGNX)

Wedbush analyst Andreas Argyrides reiterated a Hold rating on RegenXBio (RGNX – Research Report) today and set a price target of $29.00. The company's shares closed last Thursday at $29.56, close to its 52-week low of $27.02. According to TipRanks.com, Argyrides is a 1-star analyst with an average return of -7.1% and a 25.0% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Clearside Biomedical, Kala Pharmaceuticals, and Unity Biotechnology. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RegenXBio with a $56.00 average price target. See the top stocks recommended by analysts >> RegenXBio's market cap is currently $1.

Catie Powers on TipRanks | January 6, 2022

REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

Potential one-time gene therapy for the treatment of Duchenne includes a novel, optimized microdystrophin transgene and REGENXBIO's proprietary NAV

Yahoo | January 6, 2022

Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate

Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.

Yahoo | December 3, 2021

REGENXBIO (NASDAQ:RGNX shareholders incur further losses as stock declines 7.6% this week, taking three-year losses to 48%

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Yahoo | November 29, 2021

4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio

Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

Yahoo | November 26, 2021

REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

Yahoo | November 23, 2021

RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne). Duchenne is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. RGX-202 is designed to deliver optimized microdystrophin transgene with a unique C-terminal domain and a muscle-specific promoter to support targeted the

Yahoo | November 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6624 seconds.